The Food and Drug Administration has granted approval to a latest combination therapy for adults battling relapsed or refractory multiple myeloma, a cancer affecting plasma cells. The treatment, consisting of teclistamab-cqyv in combination with daratumumab hyaluronidase-fihj, offers a promising new option for patients who have previously undergone at least one line of therapy. This approval marks the third under the FDA’s Commissioner’s National Priority Voucher pilot program, highlighting the urgent need for innovative treatments in this challenging area of oncology.
Multiple myeloma is a particularly difficult cancer to treat long-term, often relapsing after initial responses. This new combination therapy aims to address that challenge by providing a more effective regimen, particularly for those who have seen limited success with existing treatments. The FDA’s decision was based on compelling data from the Phase 3 MajesTEC-3 clinical trial, demonstrating significant improvements in both progression-free survival and overall survival.
MajesTEC-3 Trial Results Show Significant Benefit
The MajesTEC-3 trial, a randomized study involving 587 patients, compared the teclistamab-daratumumab combination to standard care regimens – either daratumumab hyaluronidase-fihj with pomalidomide and dexamethasone, or daratumumab hyaluronidase-fihj with bortezomib and dexamethasone. Results published by Healio showed a remarkable 83% reduction in the risk of disease progression or death for patients receiving the combination therapy (HR = 0.17. 95% CI, 0.12 – 0.23). Median overall survival was also significantly improved (HR = 0.46; 95% CI, 0.32-0.65).
Perhaps most striking were the long-term outcomes. The data revealed a 3-year progression-free survival rate of 83.4% among patients treated with the teclistamab-daratumumab combination, compared to just 29.7% in the control group. Similarly, the 3-year overall survival rate was 83.3% versus 65%, demonstrating a substantial and sustained benefit for those receiving the new treatment.
Expert Perspective on a Changing Treatment Landscape
“This new treatment option can redefine how we approach relapsed or refractory multiple myeloma treatment by giving health care providers a regimen with improvement in PFS and OS and a well-characterized safety profile,” said Luciano J. Costa, MD, professor of multiple myeloma and director of the multiple myeloma research and treatment program at the University of Alabama at Birmingham, in a Johnson & Johnson press release. Dr. Costa emphasized the importance of utilizing effective therapies earlier in the treatment course, given the tendency for multiple myeloma to relapse and become less responsive to treatment over time. He also highlighted the potential for reduced toxicity due to the steroid-sparing nature of the regimen.
Safety Considerations and Adverse Events
As with any cancer treatment, the teclistamab-daratumumab combination is associated with potential side effects. The most commonly reported adverse events included hypogammaglobulinemia, upper respiratory tract infection, cough, diarrhea, musculoskeletal pain, COVID-19, pneumonia, injection site reaction, fatigue, fever, headache, nausea, gastroenteritis and weight loss, according to the FDA. Serious adverse events occurred in 70.7% of patients receiving the combination therapy, compared to 62.4% in the control group. While treatment discontinuations due to adverse events were less frequent in the combination group (4.6% vs. 5.5%), grade 5 treatment-emergent adverse events were more common (7.1% vs. 5.9%).
Prescribing information for teclistamab includes a boxed warning regarding the risk of life-threatening or fatal cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity. Healthcare providers should be aware of these potential risks and monitor patients accordingly.
This approval also expands the use of teclistamab as a monotherapy, now receiving full traditional approval for patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
The evolving treatment landscape for multiple myeloma offers renewed hope for patients facing this challenging disease. Further research will continue to refine treatment strategies and improve outcomes. As the FDA continues to prioritize the development of novel therapies through programs like the National Priority Voucher pilot program, patients can anticipate further advancements in the fight against multiple myeloma.
Disclaimer: The information provided in this article is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this new treatment option? Share your perspective in the comments below.
